FDA Commissioner Marty Makary fast-tracked research for three companies developing psychedelic treatments after President Trump signed an executive order directing federal agencies to expand access to emerging psychedelic therapies. The order aims to tackle growing rates of depression, anxiety, post-traumatic stress disorder, and other serious mental health conditions.
Accelerated Research Timeline
The FDA issued national priority vouchers to three companies to begin studying psilocybin for treatment-resistant depression and major depressive disorder, as well as methylone for PTSD. According to the press release, the agency’s actions represent a step forward “to confront our nation’s mental health crisis head-on, especially for our veterans.” Health and Human Services Secretary Robert F. Kennedy Jr. stated: “The FDA will prioritize therapies with Breakthrough Therapy designation, where early evidence shows meaningful improvement over existing options for serious mental illness.”
Psychedelic Context
The agency also allowed research into ibogaine-related compounds, with the FDA Commissioner noting that with the accelerated process, the FDA could potentially approve the first psychedelic drug more quickly. The FDA’s priority voucher program operates as an effort to speed up review for drugs deemed urgently needed, potentially cutting approval time from a year to just a few months. Research into psychedelics has been limited, as the drugs are illegal in the U.S., with any real-world effects based on anecdotal reports and usage in other countries. Critics argue the program could undermine trust in the FDA’s regulatory process by opening doors for political favoritism.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://us.headtopics.com/news/fda-fast-tracks-psychedelic-drug-research-following-trump-82635297